Evidence map›Paper›PMID 35629239›Full record

ArticleJournal of personalized medicine2022

Differences in Willingness to Undergo

Yoon Jung Chang, Seungyeon Cho, Jungnam Joo, Kum Hei Ryu, Sangwon Lee, Juhee Cho, Myong Cheol Lim, So-Youn Jung, Jai Hong Han, Eun Sook Lee and 1 more

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Risk-reducing decisions regarding germlineJournal of medical genetics · 2024
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yoon Jung ChangDivision of Cancer Control & Policy, National Cancer Control Institute, National Cancer Center, Goyang 10408, Korea.ORCID 0000-0001-7750-4213
Seungyeon ChoDivision of Cancer Control & Policy, National Cancer Control Institute, National Cancer Center, Goyang 10408, Korea.
Jungnam JooOffice of Biostatistics Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20852, USA.
Kum Hei RyuCenter for Cancer Prevention & Detection, National Cancer Center Hospital, Goyang 10408, Korea.
Sangwon LeeCancer Data Center, National Cancer Control Institute, National Cancer Center, Goyang 10408, Korea.ORCID 0000-0002-2587-8915
Juhee ChoCenter for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Myong Cheol LimDepartment of Cancer Control and Policy, National Cancer Center Graduate School of Cancer Science and Policy, Goyang 10408, Korea.ORCID 0000-0001-8964-7158
So-Youn JungCenter for Breast Cancer, National Cancer Center Hospital, Goyang 10408, Korea.
Jai Hong HanCenter for Breast Cancer, National Cancer Center Hospital, Goyang 10408, Korea.
Eun Sook LeeImmuno-Oncology Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang 10408, Korea.
Sun-Young KongCancer Outcome & Quality Improvement Branch, Research Institute, National Cancer Center, Goyang 10408, Korea.ORCID 0000-0003-0620-4058

Funding

National Cancer Center, Republic of Korea 2110181
6 · The paper itself

Abstract

We aimed to understand the decision-making process related to the willingness to undergo BRCA1/2 genetic testing, risk-reducing salpingo-oophorectomy (RRSO), or risk-reducing mastectomy (RRM) among the general public, cancer patients, and healthcare professionals in South Korea. In total, 3444 individuals (1496 from the general public, 1500 cancer patients, 108 clinicians, and 340 researchers) completed a survey addressing genetic testing and related risk management options in a hypothetical scenario. Differences in intent and associated factors for undergoing the above procedures or sharing test results were analyzed. Overall, 67% of participants were willing to undergo BRCA1/2 testing, with proportions of the general public (58%), cancer patients (70%), clinicians (88%), and researchers (90%). The willingness to undergo RRSO was highest among clinicians (58%), followed by among patients (38%), the general public (33%), and researchers (32%) (p < 0.001). Gender, age, education level, and household income were associated with willingness to undergo genetic testing, RRM, and RRSO (p < 0.05). The intent for undergo genetic testing, RRM, and RRSO were affected by many factors. Finally, 69% of the general public intended to share information with family, while this percentage was 92%, 91%, and 94% for patients, clinicians, and researchers, respectively (p < 0.05). These results highlight the requirement for developing targeted educational materials and counseling strategies for facilitating informed decision making.

Indexed as

BRCA1BRCA2clinical decision makinggenetic counselinggenetic testinginformation disseminationmastectomyprophylactic surgical proceduresalpingo-oophorectomy

Identifiers

PMID35629239
PMCPMC9147340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.